Relapse and cytogenetic evolution in myeloid neoplasms

Area of Science:

• Hematology
• Cytogenetics
• Oncology

Background:

• Cytogenetic findings are central to diagnosing myeloid neoplasms per WHO classification.
• Karyotype abnormalities can change over time, exhibiting evolution or regression.
• Understanding these patterns is key for managing myeloid malignancies.

Purpose of the Study:

• To analyze cytogenetic evolution patterns in myeloid neoplasms.
• To investigate the significance of karyotype changes in chronic myelogenous leukemia (CML) and acute myeloid leukemia (AML).
• To assess the prognostic value of cytogenetic evolution in patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT).

Main Methods:

• Review of cytogenetic evolution pathways in CML, including major and minor route abnormalities.
• Analysis of karyotype changes in Ph-negative cells of CML patients treated with imatinib.
• Examination of karyotype evolution in AML patients post-chemotherapy and post-allo-HCT.

Main Results:

• Cytogenetic evolution in CML follows specific major and minor routes.
• Ph-negative karyotype abnormalities in CML patients treated with imatinib require further investigation.
• Karyotype evolution in AML, particularly post-allo-HCT, is associated with shorter remission and survival.
• Detection of karyotype abnormalities post-allo-HCT often precedes relapse within 90 days.

Conclusions:

• Cytogenetic evolution is a non-random process in myeloid neoplasms with prognostic implications.
• Monitoring karyotype changes is essential for managing CML and AML, especially after allo-HCT.
• Further research is needed to understand the impact of chemotherapy and the bone marrow environment on karyotype stability.